AstraZeneca (Japan)

40.3k citations
1.0k papers ·

Impact in

Papers in

AstraZeneca (Japan)

817 papers receiving 34.3k citations

Peers

AstraZeneca (Japan)
Comparison fields: 5 of 202
  • Oncology 10.4k
  • Pulmonary and Respiratory Medicine 11.5k
  • Cancer Research 3.8k
  • Immunology 3.4k
  • Molecular Biology 10.6k
Replace Foundation for Biomedical Research and Innovation with:
Foundation for Biomedical Research and Innovation Japan
Taiho Pharmaceutical (Japan) Japan
Merck Biopharma Co., Ltd. (Japan) Japan
Systems Biology Institute Japan
Osaka International University Japan
Mochida Pharmaceutical (Japan) Japan
Oita Medical Center Japan
Children's Research Hospital Japan
Osaka Red Cross Hospital Japan
Boehringer Ingelheim (Japan) Japan
AstraZeneca (Japan) relative to Foundation for Biomedical Research and Innovation Japan Foundation for Biomedical Research and Innovation's profile →
Citations per field
00.5×2.8×
Foundation for Biomedical Research and Innovation · 1×
Citations per year

Countries citing scholars working at AstraZeneca (Japan)

Since Specialization
Citations

This map shows the geographic impact of research produced by authors working at AstraZeneca (Japan). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at AstraZeneca (Japan) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AstraZeneca (Japan) more than expected).

Fields of papers published by authors at AstraZeneca (Japan)

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers affiliated with AstraZeneca (Japan) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with AstraZeneca (Japan) at the time of their publication.

About AstraZeneca (Japan)

In recent decades, authors affiliated with AstraZeneca (Japan) have published 1.0k papers, which have received a total of 40.3k indexed citations . Scholars at this organization have produced 212 papers in Oncology, 239 papers in Pulmonary and Respiratory Medicine, 55 papers in Genetics, 77 papers in Endocrinology, Diabetes and Metabolism and 50 papers in Cancer Research on the topics of Lung Cancer Treatments and Mutations (97 papers), Cancer Immunotherapy and Biomarkers (62 papers), Diabetes Treatment and Management (53 papers), Asthma and respiratory diseases (49 papers), Chronic Lymphocytic Leukemia Research (44 papers), Colorectal Cancer Treatments and Studies (35 papers), Monoclonal and Polyclonal Antibodies Research (34 papers) and Computational Drug Discovery Methods (31 papers). Their work is cited by papers focused on Oncology (10.4k citations), Pulmonary and Respiratory Medicine (11.5k citations), Cancer Research (3.8k citations), Immunology (3.4k citations) and Molecular Biology (10.6k citations). Authors at AstraZeneca (Japan) collaborate with scholars in Japan, United States and United Kingdom and have published in prestigious journals including Journal of Clinical Oncology, Cancer Research, Blood, Diabetes Obesity and Metabolism and Journal of Thoracic Oncology. Some of AstraZeneca (Japan)'s most productive authors include Ola Engkvist, Haiyi Jiang, Sumitra Thongprasert, Dmitry I. Gabrilovich, Emilio Sanseviero, Filippo Veglia, Masahiro Fukuoka, Nagahiro Saijo, Tony Mok and Yukito Ichinose.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore institutions with similar magnitude of impact